JP2022130378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022130378A5 JP2022130378A5 JP2022087418A JP2022087418A JP2022130378A5 JP 2022130378 A5 JP2022130378 A5 JP 2022130378A5 JP 2022087418 A JP2022087418 A JP 2022087418A JP 2022087418 A JP2022087418 A JP 2022087418A JP 2022130378 A5 JP2022130378 A5 JP 2022130378A5
- Authority
- JP
- Japan
- Prior art keywords
- vamp
- antibody
- detection antibody
- terminal
- cleavage product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 claims 28
- 101000879393 Aplysia californica Synaptobrevin Proteins 0.000 claims 27
- 238000003776 cleavage reaction Methods 0.000 claims 18
- 230000007017 scission Effects 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 230000000890 antigenic effect Effects 0.000 claims 15
- 238000001514 detection method Methods 0.000 claims 15
- 210000004899 c-terminal region Anatomy 0.000 claims 14
- 108010055044 Tetanus Toxin Proteins 0.000 claims 9
- 101000761935 Clostridium botulinum Botulinum neurotoxin type X Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 108030001720 Bontoxilysin Proteins 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 101000828633 Homo sapiens Synaptobrevin homolog YKT6 Proteins 0.000 claims 2
- 101000639146 Homo sapiens Vesicle-associated membrane protein 4 Proteins 0.000 claims 2
- 101000639143 Homo sapiens Vesicle-associated membrane protein 5 Proteins 0.000 claims 2
- 102100023512 Synaptobrevin homolog YKT6 Human genes 0.000 claims 2
- 108010017749 Vesicle-Associated Membrane Protein 3 Proteins 0.000 claims 2
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 claims 2
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 claims 2
- 102100031486 Vesicle-associated membrane protein 3 Human genes 0.000 claims 2
- 102100031489 Vesicle-associated membrane protein 4 Human genes 0.000 claims 2
- 102100031484 Vesicle-associated membrane protein 5 Human genes 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 230000007900 neurotoxin activity Effects 0.000 claims 2
- 108010017743 Vesicle-Associated Membrane Protein 1 Proteins 0.000 claims 1
- 102100037105 Vesicle-associated membrane protein 1 Human genes 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103017A JP2024123229A (ja) | 2016-10-18 | 2024-06-26 | 細胞性ｖａｍｐ切断アッセイ |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16194390.7A EP3312290A1 (en) | 2016-10-18 | 2016-10-18 | Cellular vamp cleavage assay |
| EP16194390.7 | 2016-10-18 | ||
| PCT/EP2017/076569 WO2018073288A1 (en) | 2016-10-18 | 2017-10-18 | Cellular vamp cleavage assay |
| JP2019519721A JP7127019B2 (ja) | 2016-10-18 | 2017-10-18 | 細胞性ｖａｍｐ切断アッセイ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519721A Division JP7127019B2 (ja) | 2016-10-18 | 2017-10-18 | 細胞性ｖａｍｐ切断アッセイ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103017A Division JP2024123229A (ja) | 2016-10-18 | 2024-06-26 | 細胞性ｖａｍｐ切断アッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022130378A JP2022130378A (ja) | 2022-09-06 |
| JP2022130378A5 true JP2022130378A5 (enExample) | 2023-03-09 |
| JP7656571B2 JP7656571B2 (ja) | 2025-04-03 |
Family
ID=57208094
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519721A Active JP7127019B2 (ja) | 2016-10-18 | 2017-10-18 | 細胞性ｖａｍｐ切断アッセイ |
| JP2022087418A Active JP7656571B2 (ja) | 2016-10-18 | 2022-05-30 | 細胞性ｖａｍｐ切断アッセイ |
| JP2024103017A Pending JP2024123229A (ja) | 2016-10-18 | 2024-06-26 | 細胞性ｖａｍｐ切断アッセイ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519721A Active JP7127019B2 (ja) | 2016-10-18 | 2017-10-18 | 細胞性ｖａｍｐ切断アッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103017A Pending JP2024123229A (ja) | 2016-10-18 | 2024-06-26 | 細胞性ｖａｍｐ切断アッセイ |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11193931B2 (enExample) |
| EP (2) | EP3312290A1 (enExample) |
| JP (3) | JP7127019B2 (enExample) |
| CN (2) | CN109844130B (enExample) |
| WO (1) | WO2018073288A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2825370A1 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
| US10179911B2 (en) | 2014-01-20 | 2019-01-15 | President And Fellows Of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
| WO2016077052A2 (en) | 2014-10-22 | 2016-05-19 | President And Fellows Of Harvard College | Evolution of proteases |
| WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
| WO2017015545A1 (en) | 2015-07-22 | 2017-01-26 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
| US11524983B2 (en) | 2015-07-23 | 2022-12-13 | President And Fellows Of Harvard College | Evolution of Bt toxins |
| US10612011B2 (en) | 2015-07-30 | 2020-04-07 | President And Fellows Of Harvard College | Evolution of TALENs |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| WO2018009903A2 (en) * | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| WO2018081282A1 (en) * | 2016-10-25 | 2018-05-03 | Cellsnap Llc | Neurotoxins and uses thereof |
| WO2019010164A1 (en) | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | Evolution of trna synthetases |
| CA3073040A1 (en) | 2017-08-25 | 2019-02-28 | President And Fellows Of Harvard College | Evolution of bont peptidases |
| WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| WO2019241649A1 (en) | 2018-06-14 | 2019-12-19 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
| KR102017240B1 (ko) * | 2018-08-23 | 2019-09-02 | 주식회사 하울바이오 | Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도 |
| US20220259269A1 (en) * | 2019-07-15 | 2022-08-18 | President And Fellows Of Harvard College | Evolved botulinum neurotoxins and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| US7227010B2 (en) * | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
| GB9411138D0 (en) * | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US5962637A (en) * | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| GB9500851D0 (en) | 1995-01-17 | 1995-03-08 | Bionvent International Ab | Method of selecting specific bacteriophages |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US6169074B1 (en) * | 1996-03-18 | 2001-01-02 | The Regents Of The University Of California | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| FR2809733B1 (fr) * | 2000-06-02 | 2004-04-30 | Inst Nat Sante Rech Med | Substrat peptidique reconnu par la toxine botulique de type bont/b et son utilisation pour doser et/ou detecter ladite toxine ou des inhibiteurs correspondants |
| WO2002036758A2 (en) * | 2000-11-06 | 2002-05-10 | United States Army Medical Research And Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| GB0115581D0 (en) * | 2001-06-26 | 2001-08-15 | Glaxo Group Ltd | Method of mass spectometry |
| GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| US7611856B2 (en) | 2003-11-05 | 2009-11-03 | Los Alamos National Security, Llc | Mass spectrometry-based methods for detection and differentiation of botulinum neurotoxins |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| EP1982997B1 (en) | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| GB0425795D0 (en) | 2004-11-24 | 2004-12-22 | Givaudan Sa | Composition |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| CA2588292C (en) | 2004-12-01 | 2019-01-15 | Health Protection Agency | Non-cytotoxic protein conjugates |
| JP2008535486A (ja) | 2005-03-15 | 2008-09-04 | アラーガン、インコーポレイテッド | クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素 |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| JP5134540B2 (ja) | 2005-09-19 | 2013-01-30 | アラーガン、インコーポレイテッド | クロストリジウム毒素活性化クロストリジウム毒素 |
| WO2007106115A1 (en) | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| US8753831B2 (en) * | 2007-06-05 | 2014-06-17 | City Of Hope | Methods for detection of botulinum neurotoxin |
| CN101932936B (zh) * | 2007-09-14 | 2016-04-27 | 拜奥麦迪逊公司 | 利用切割序列和间隔子的共振能量转移测定 |
| US8940477B2 (en) * | 2007-11-08 | 2015-01-27 | Wisconsin Alumni Research Foundation | Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action |
| CN107446053A (zh) | 2008-06-12 | 2017-12-08 | 益普生生物创新有限公司 | 癌症的抑制 |
| EP2719392B1 (en) | 2008-06-12 | 2019-07-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatment of acromegaly |
| GB0815264D0 (en) | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| US20100303788A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases |
| US20100303791A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
| US20100303783A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases |
| CN102573875A (zh) | 2009-08-14 | 2012-07-11 | 阿勒根公司 | 使用速激肽再靶向内肽酶治疗癌症的方法 |
| EP2464367A2 (en) | 2009-08-14 | 2012-06-20 | Allergan, Inc. | Methods of treating cancer using neurotrophin retargeted endopeptidases |
| AU2010282289A1 (en) | 2009-08-14 | 2012-03-15 | Allergan, Inc. | Methods of treating cancer using galanin retargeted endpeptidases |
| AU2010282285A1 (en) | 2009-08-14 | 2012-03-15 | Allergan, Inc. | Methods of treating cancer using opioid retargeted endpeptidases |
| CN102574899A (zh) | 2009-08-14 | 2012-07-11 | 阿勒根公司 | 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法 |
| US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
| US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
| US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
| US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
| US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
| US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
| WO2012135304A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Vagal nerve-based disorders |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| WO2013011055A1 (en) * | 2011-07-19 | 2013-01-24 | ETH Zürich | Means and methods for determining clostridial neurotoxins |
| US20140287433A1 (en) * | 2011-07-19 | 2014-09-25 | ETH Zürich | Means and methods for determining clostridial neurotoxins |
| HUE037509T2 (hu) * | 2011-09-29 | 2018-09-28 | Cellsnap Llc | Készítmények és eljárások toxigenicitás meghatározására |
| CN104736166B (zh) | 2012-05-30 | 2018-02-16 | 哈佛大学校长及研究员协会 | 工程化的肉毒神经毒素 |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| AU2013349725B2 (en) * | 2012-11-21 | 2016-05-12 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determination of botulinum neurotoxin biological activity |
| GB201303108D0 (en) | 2013-02-21 | 2013-04-10 | Syntaxin Ltd | Therapeutics for suppressing osteoporosis |
| CN105339790B (zh) * | 2013-06-28 | 2018-04-17 | 莫茨制药有限及两合公司 | 用于确定神经毒素多肽在细胞中的生物活性的工具和方法 |
| GB201312295D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Suppression of itch |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
-
2016
- 2016-10-18 EP EP16194390.7A patent/EP3312290A1/en not_active Ceased
-
2017
- 2017-10-18 EP EP17793604.4A patent/EP3529370A1/en active Pending
- 2017-10-18 CN CN201780063220.0A patent/CN109844130B/zh active Active
- 2017-10-18 CN CN202411324418.8A patent/CN119529053A/zh active Pending
- 2017-10-18 JP JP2019519721A patent/JP7127019B2/ja active Active
- 2017-10-18 WO PCT/EP2017/076569 patent/WO2018073288A1/en not_active Ceased
- 2017-10-18 US US16/335,358 patent/US11193931B2/en active Active
-
2021
- 2021-10-22 US US17/451,900 patent/US12493035B2/en active Active
-
2022
- 2022-05-30 JP JP2022087418A patent/JP7656571B2/ja active Active
-
2024
- 2024-06-26 JP JP2024103017A patent/JP2024123229A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022130378A5 (enExample) | ||
| JP2024123229A5 (enExample) | ||
| Tozzoli et al. | Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology | |
| RU2491293C2 (ru) | Иммунологические анализы активности ботулинического токсина серотипа а | |
| Magni et al. | Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis | |
| US8093044B2 (en) | Methods for identifying inhibitors of botulinum neurotoxins | |
| JP2019532651A5 (enExample) | ||
| JP2010162016A5 (enExample) | ||
| WO2018073288A1 (en) | Cellular vamp cleavage assay | |
| Angkawanish et al. | The elephant interferon gamma assay: a contribution to diagnosis of tuberculosis in elephants | |
| Croft et al. | Use of Luminex xMAP-derived Bio-Plex bead-based suspension array for specific detection of PPV W and characterization of epitopes on the coat protein of the virus | |
| JP5689113B2 (ja) | ニューロトキシンポリペプチドの量の測定とその触媒及びタンパク質分解活性の測定のための手段及び方法 | |
| RU2018138782A (ru) | Антитела к фактору ix padua | |
| Rosen et al. | A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase–liquid chromatography–tandem mass spectrometry/multiple reaction monitoring assay | |
| CN111018974B (zh) | 一种抗人心肌肌钙蛋白i的重组抗体 | |
| RU2023128330A (ru) | Анализ расщепления клеточного vamp | |
| CN102597769B (zh) | 用于测定未加工和部分加工的神经毒素a多肽的系统 | |
| Zhang et al. | Targeting novel LPXTG surface proteins with monoclonal antibodies for immunomagnetic separation of Listeria monocytogenes | |
| EP4459281A1 (en) | Detection method and detection reagent | |
| Vale et al. | Evaluation from a B-cell epitope-based chimeric protein for the serodiagnosis of tegumentary and visceral leishmaniasis | |
| JP5230397B2 (ja) | 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法 | |
| EP4580665A2 (en) | Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis | |
| CN111018973B (zh) | 一种抗人心肌肌钙蛋白i的重组抗体 | |
| Pizzano et al. | Antigenicity of the 139− 149 αs1-casein region in different species revealed by ELISA and immunoblotting using antipeptide antibodies | |
| Schneyer | Measurement of activin in physiological fluids |